Lexaria Bioscience Corp.(LEXX)Earnings, Financials & Key Ratios
LEXX•NASDAQ
Price updated Jun 19, 2026
AboutLexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Show more
- Revenue$706K+52.0%
- EBITDA-$12M-105.0%
- Net Income-$12M-105.4%
- EPS (Diluted)-0.66-40.4%
- Gross Margin83.2%+0.8%
- EBITDA Margin-1631.55%-34.8%
- Operating Margin-1647.97%-34.3%
- Net Margin-1686%-35.1%
- ROE-231.96%-106.9%
LEXX Key Insights
Lexaria Bioscience Corp. (LEXX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 17.5%
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 9 (bottom 9%)
- ✗Shares diluted 45.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LEXX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LEXX Price & Volume
Lexaria Bioscience Corp. (LEXX) stock price & volume — 10-year historical chart
Loading chart...
LEXX Growth Metrics
Lexaria Bioscience Corp. (LEXX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years47.28%
5 Years17.53%
3 Years40.34%
TTM5.05%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-47.45%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-10.44%
Return on Capital
10 Years-162.84%
5 Years-117.63%
3 Years-151.75%
Last Year-222.65%
LEXX Peer Comparison
Lexaria Bioscience Corp. (LEXX) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATAI | 1.49B | 4.06 | -1.40 | 12.28% | -190.19% | -366.21% | 0.01 | |
 CMPS | 1.2B | 12.53 | -4.07 | -151.02% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% | ||||
 NRXP | 68.62M | 3.97 | -2.96 | -10.7% | ||||
 CYBN | 303.86M | 6.09 | -13.66 | -81% | ||||
 CRON | 1.01B | 2.71 | -110.61 | 64.4% | -0.98% | -0.18% | 0.00 | |
 CGC | 372.36M | 0.97 | -1.55 | 79.81% | -117.39% | -49.5% | 0.33 | |
 TLRY | 551.15M | 4.73 | -0.14 | 4.84% | -252.55% | -136.55% | 0.22 |
Compare LEXX vs Peers
Lexaria Bioscience Corp. (LEXX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LEXX Income Statement
Lexaria Bioscience Corp. (LEXX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Aug'17 | Aug'18 | Aug'19 | Aug'20 | Aug'21 | Aug'22 | Aug'23 | Aug'24 | Aug'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 63.64K | 433.29K | 222.61K | 314.79K | 722.74K | 255.4K | 226.21K | 464.28K | 705.92K | 522K |
Revenue Growth % | 56.29% | 580.85% | -48.62% | 41.41% | 129.59% | -64.66% | -11.43% | 105.24% | 52.05% | 5.05% |
Cost of Goods Sold | 31.24K | 27.49K | 416.64K | 245.47K | 175.35K | 208.68K | 172.25K | 80.97K | 118.57K | 78.83K |
COGS % of Revenue | 49.09% | 6.35% | 187.16% | 77.98% | 24.26% | 81.71% | 76.14% | 17.44% | 16.8% | - |
Gross Profit | 32.4K▲ 0% | 405.8K▲ 1152.4% | -194.03K▼ 147.8% | 69.32K▲ 135.7% | 547.39K▲ 689.6% | 46.71K▼ 91.5% | 53.96K▲ 15.5% | 383.3K▲ 610.3% | 587.35K▲ 53.2% | 443.17K▲ 0% |
Gross Margin % | 50.91% | 93.66% | -87.16% | 22.02% | 75.74% | 18.29% | 23.86% | 82.56% | 83.2% | 84.9% |
Gross Profit Growth % | 687.4% | 1152.41% | -147.82% | 135.73% | 689.63% | -91.47% | 15.52% | 610.32% | 53.23% | - |
Operating Expenses | 1.96M | 7.02M | 3.95M | 4.2M | 6.07M | 6.55M | 6.59M | 6.08M | 12.22M | 10.99M |
OpEx % of Revenue | 3073.35% | 1619.94% | 1773.48% | 1333.65% | 839.58% | 2563.69% | 2912.36% | 1309.26% | 1731.17% | - |
Selling, General & Admin | 1.83M | 6.51M | 3.39M | 3.81M | 4.81M | 4.7M | 2.92M | 3.72M | 3.98M | 4.04M |
SG&A % of Revenue | 2880.4% | 1503.2% | 1520.61% | 1210.69% | 664.85% | 1842.19% | 1291.41% | 800.82% | 564.08% | - |
Research & Development | 54.19K | 492.86K | 555.73K | 387.07K | 1.26M | 1.84M | 3.67M | 2.36M | 8.24M | 6.96M |
R&D % of Revenue | 85.14% | 113.75% | 249.64% | 122.96% | 174.74% | 721.5% | 1620.95% | 508.44% | 1167.09% | - |
Other Operating Expenses | -68.61K | -12.97K | -7.18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -1.92M▲ 0% | -6.61M▼ 243.8% | -4.14M▲ 37.4% | -4.13M▲ 0.3% | -5.52M▼ 33.7% | -6.5M▼ 17.8% | -6.53M▼ 0.5% | -5.7M▲ 12.8% | -11.63M▼ 104.3% | -10.55M▲ 0% |
Operating Margin % | -3022.44% | -1526.28% | -1860.64% | -1311.63% | -763.84% | -2545.4% | -2888.5% | -1226.7% | -1647.97% | -2021.04% |
Operating Income Growth % | -52.7% | -243.82% | 37.37% | 0.32% | -33.71% | -17.76% | -0.51% | 12.84% | -104.26% | - |
EBITDA | -1.92M | -6.61M | -4.08M | -3.98M | -5.37M | -6.35M | -6.39M | -5.62M | -11.52M | -10.47M |
EBITDA Margin % | -3020.1% | -1525.75% | -1833.44% | -1265.22% | -743.42% | -2487.87% | -2824.23% | -1210.3% | -1631.55% | -2005.94% |
EBITDA Growth % | -52.66% | -243.97% | 38.26% | 2.42% | -34.9% | -18.26% | -0.55% | 12.04% | -104.97% | -47.1% |
D&A (Non-Cash Add-back) | 1.49K | 2.31K | 60.55K | 146.09K | 147.6K | 146.91K | 145.4K | 76.15K | 115.85K | 78.83K |
EBIT | -1.92M | -6.61M | -4.16M | -4.15M | -4.16M | -7.38M | -6.71M | -5.81M | -11.91M | -10.8M |
Net Interest Income | -6.01K | 0 | 0 | 0 | 0 | 0 | 43.19K | 14.31K | 3.02K | 3.02K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 43.19K | 14.31K | 3.02K | 3.02K |
Interest Expense | 6.01K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -6.01K | 4K | -16.43K | -19.89K | 1.36M | -882.81K | -178.5K | -113.36K | -278.06K | -250.68K |
Pretax Income | -1.93M▲ 0% | -6.61M▼ 242.5% | -4.16M▲ 37.1% | -4.15M▲ 0.2% | -4.16M▼ 0.4% | -7.38M▼ 77.3% | -6.71M▲ 9.1% | -5.81M▲ 13.5% | -11.91M▼ 105.1% | -10.8M▲ 0% |
Pretax Margin % | -3031.89% | -1525.36% | -1868.03% | -1317.94% | -576.16% | -2891.06% | -2967.41% | -1251.12% | -1687.36% | -2069.06% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.79K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.02% |
Net Income | -1.87M▲ 0% | -6.6M▼ 253.0% | -4.1M▲ 37.9% | -3.93M▲ 4.0% | -4.03M▼ 2.4% | -7.27M▼ 80.5% | -6.66M▲ 8.3% | -5.8M▲ 13.0% | -11.9M▼ 105.4% | -10.79M▲ 0% |
Net Margin % | -2937.31% | -1522.97% | -1841.53% | -1249.71% | -557.19% | -2846.3% | -2946.36% | -1248.25% | -1686% | -2067.65% |
Net Income Growth % | -53.88% | -253.02% | 37.88% | 4.04% | -2.36% | -80.51% | 8.31% | 13.05% | -105.37% | -47.45% |
Net Income (Continuing) | -1.93M | -6.61M | -4.16M | -4.15M | -4.16M | -7.38M | -6.71M | -5.81M | -11.91M | -10.8M |
Discontinued Operations | 0 | 0 | 0 | 64.18K | -22K | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -238.48K | 0 | 107.67K | -42.94K | -202.09K | -316.41K | -364.04K | -377.35K | -386.94K | -389.44K |
EPS (Diluted) | -0.95▲ 0% | -2.79▼ 193.7% | -1.62▲ 41.9% | -1.42▲ 12.3% | -0.92▲ 35.2% | -1.24▼ 34.8% | -1.01▲ 18.5% | -0.47▲ 53.5% | -0.66▼ 40.4% | -0.50▲ 0% |
EPS Growth % | -14.46% | -193.68% | 41.94% | 12.35% | 35.21% | -34.78% | 18.55% | 53.47% | -40.43% | -10.44% |
EPS (Basic) | -0.95 | -2.79 | -1.62 | -1.42 | -0.92 | -1.24 | -1.01 | -0.47 | -0.66 | - |
Diluted Shares Outstanding | 1.96M | 2.37M | 2.59M | 2.77M | 4.39M | 5.89M | 6.61M | 12.38M | 18M | 21.38M |
Basic Shares Outstanding | 1.96M | 2.37M | 2.59M | 2.77M | 4.39M | 5.89M | 6.61M | 12.38M | 18M | 21.38M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
LEXX Balance Sheet
Lexaria Bioscience Corp. (LEXX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Aug'17 | Aug'18 | Aug'19 | Aug'20 | Aug'21 | Aug'22 | Aug'23 | Aug'24 | Aug'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 2.8M | 2.28M | 1.82M | 1.93M | 12.44M | 6.98M | 2.2M | 7.9M | 3.47M | 5.36M |
Cash & Short-Term Investments | 2.53M | 1.74M | 1.35M | 1.31M | 11.75M | 6.16M | 1.48M | 6.56M | 1.97M | 4.42M |
Cash Only | 2.53M | 1.73M | 1.29M | 1.29M | 10.92M | 5.81M | 1.35M | 6.5M | 1.8M | 4.28M |
Short-Term Investments | 0 | 10.15K | 64.21K | 19.32K | 833.84K | 347.33K | 125.64K | 55.81K | 165.36K | 143.27K |
Accounts Receivable | 45.29K | 265.75K | 273.14K | 313.93K | 342.4K | 201.78K | 175.25K | 154.48K | 368.36K | 88.04K |
Days Sales Outstanding | 259.78 | 223.87 | 447.86 | 363.99 | 172.92 | 288.38 | 282.77 | 121.44 | 190.46 | 200.28 |
Inventory | 67.17K | 87.23K | 127.4K | 116.87K | 29.65K | 38.42K | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 784.89 | 1.16K | 111.61 | 173.78 | 61.72 | 67.2 | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 64.68K | 147.78K | 856.39K | 902.28K | 823.88K | 856.41K | 884.21K | 969.8K | 706.78K | 687.68K |
Property, Plant & Equipment | 1.86K | 1.24K | 591.26K | 610.28K | 459.25K | 367.95K | 421.59K | 389.55K | 334.94K | 315.61K |
Fixed Asset Turnover | 34.29x | 350.27x | 0.38x | 0.52x | 1.57x | 0.69x | 0.54x | 1.19x | 2.11x | 1.53x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 62.83K | 146.54K | 265.13K | 292K | 364.62K | 488.46K | 462.63K | 516.68K | 307.82K | 308.06K |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 63.58K | 64.01K | 64.01K |
Total Assets | 2.86M▲ 0% | 2.43M▼ 15.0% | 2.68M▲ 10.0% | 2.83M▲ 5.7% | 13.27M▲ 369.1% | 7.83M▼ 41.0% | 3.08M▼ 60.6% | 8.87M▲ 187.5% | 4.18M▼ 52.9% | 6.05M▲ 0% |
Asset Turnover | 0.02x | 0.18x | 0.08x | 0.11x | 0.05x | 0.03x | 0.07x | 0.05x | 0.17x | 0.08x |
Asset Growth % | 404.76% | -14.98% | 10.01% | 5.72% | 369.08% | -40.95% | -60.63% | 187.54% | -52.92% | -87.24% |
Total Current Liabilities | 92.35K | 43.64K | 184.51K | 225.92K | 153.28K | 194.04K | 267.74K | 1.1M | 1.49M | 1.46M |
Accounts Payable | 32.57K | 14.38K | 31.46K | 45.08K | 104.89K | 120.15K | 225.04K | 1.06M | 1.37M | 1.3M |
Days Payables Outstanding | 380.61 | 190.89 | 27.56 | 67.03 | 218.34 | 210.14 | 476.87 | 4.77K | 4.2K | 6.84K |
Short-Term Debt | 0 | 0 | 0 | 0 | 7.93K | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 17.08K | 0 | 0 | 44.26K | 0 | 0 | 0 | 4.96K | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Current Ratio | 30.27x | 52.34x | 9.86x | 8.53x | 81.18x | 35.96x | 8.22x | 7.18x | 2.32x | 3.68x |
Quick Ratio | 29.54x | 50.34x | 9.17x | 8.01x | 80.99x | 35.76x | 8.22x | 7.18x | 2.32x | 3.68x |
Cash Conversion Cycle | 664.06 | 1.19K | 531.9 | 470.74 | 16.3 | 145.43 | - | - | - | -6.64K |
Total Non-Current Liabilities | 0 | 0 | 0 | 120.06K | 49.99K | 7.4K | 136.17K | 109.32K | 78.9K | 70.82K |
Long-Term Debt | 0 | 0 | 0 | 30.67K | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 89.39K | 49.99K | 7.4K | 136.17K | 109.32K | 78.9K | 330.82K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 92.35K | 43.64K | 184.51K | 345.98K | 203.26K | 201.44K | 403.91K | 1.21M | 1.57M | 1.53M |
Total Debt | 42.69K | 7.86K | 0 | 156.1K | 97.32K | 49.99K | 163.97K | 137.37K | 109.32K | 101.92K |
Net Debt | -2.49M | -1.72M | -1.29M | -1.14M | -10.82M | -5.76M | -1.19M | -6.36M | -1.69M | -4.18M |
Debt / Equity | 0.02x | 0.00x | - | 0.06x | 0.01x | 0.01x | 0.06x | 0.02x | 0.04x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.40x |
Interest Coverage | -319.78x | - | - | - | - | - | - | - | - | - |
Total Equity | 2.77M▲ 0% | 2.39M▼ 13.7% | 2.49M▲ 4.3% | 2.48M▼ 0.3% | 13.06M▲ 426.3% | 7.63M▼ 41.6% | 2.68M▼ 64.9% | 7.66M▲ 185.8% | 2.6M▼ 66.0% | 4.52M▲ 0% |
Equity Growth % | 3053.97% | -13.72% | 4.29% | -0.34% | 426.28% | -41.57% | -64.89% | 185.78% | -66.02% | -154.89% |
Book Value per Share | 1.41 | 1.01 | 0.96 | 0.90 | 2.97 | 1.30 | 0.41 | 0.62 | 0.14 | 0.21 |
Total Shareholders' Equity | 3.01M | 2.39M | 2.38M | 2.53M | 13.27M | 7.95M | 3.04M | 8.04M | 2.99M | 4.91M |
Common Stock | 67.98K | 75.53K | 78.79K | 3K | 5.73K | 5.95K | 8.09K | 15.81K | 19.56K | 22.23K |
Retained Earnings | -13.17M | -19.77M | -23.87M | -27.8M | -31.83M | -39.1M | -45.76M | -51.56M | -63.46M | -65.06M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -14.25K | 0 | 0 | 0 | 0 | 0 | -19.82K | -70.33K | -76.08K |
Minority Interest | -238.48K | 0 | 107.67K | -42.94K | -202.09K | -316.41K | -364.04K | -377.35K | -386.94K | -389.44K |
LEXX Cash Flow Statement
Lexaria Bioscience Corp. (LEXX) cash flow — operating, investing & free cash flow history
| Metric | Aug'17 | Aug'18 | Aug'19 | Aug'20 | Aug'21 | Aug'22 | Aug'23 | Aug'24 | Aug'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.55M | -2.52M | -3.01M | -2.62M | -3.99M | -4.88M | -5.88M | -4.96M | -10.45M | -8.71M |
Operating CF Margin % | -2429.18% | -581.13% | -1350.14% | -831.91% | -552.02% | -1910.5% | -2599.92% | -1068.11% | -1480.39% | - |
Operating CF Growth % | -133.93% | -62.88% | -19.36% | 12.87% | -52.35% | -22.3% | -20.53% | 15.68% | -110.74% | -300.61% |
Net Income | -1.93M | -6.61M | -4.16M | -4.08M | -4.19M | -7.38M | -6.71M | -5.81M | -11.91M | -10.79M |
Depreciation & Amortization | 1.49K | 2.31K | 60.55K | 146.09K | 147.6K | 102.72K | 145.4K | 76.15K | 87.83K | 71.5K |
Stock-Based Compensation | 113.04K | 2.6M | 626.69K | 1.14M | 410.01K | 752.59K | 170.38K | 492.24K | 859.49K | 834.97K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 570.15K | 1.86M | 385.93K | 374.83K | -424.66K | 2M | 372.25K | 174.71K | 318.15K | 324.06K |
Working Capital Changes | -301.12K | -371.23K | 79.68K | -194.36K | 63.53K | -351.48K | 143.26K | 106.56K | 195.58K | 863.34K |
Change in Receivables | -7.71K | -245.46K | -138.64K | -90.78K | 189.58K | -137.49K | 26.54K | -50.57K | -214.32K | 175.45K |
Change in Inventory | -1.06K | -33.02K | -47.34K | 4.21K | 95.04K | -1.98K | 43.07K | 0 | 0 | 0 |
Change in Payables | -40.44K | 3.21K | 100.63K | -49.49K | 13.8K | 50.73K | 88.49K | 826.47K | 0 | 0 |
Cash from Investing | -9.7K | -155.4K | -769.16K | -26.84K | 193.88K | -180.64K | -169.61K | -188.6K | -243.02K | -210.31K |
Capital Expenditures | -9.7K | -85.4K | -646.18K | -33.65K | -79.49K | -49.19K | -33.75K | -43.01K | -24.65K | -5.1K |
CapEx % of Revenue | 15.24% | 19.71% | 290.28% | 10.69% | 11% | 19.26% | 14.92% | 9.26% | 3.49% | 0.98% |
Acquisitions | 0 | -70K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -122.98K | 0 | 273.37K | -131.45K | -135.86K | -145.59K | -218.37K | -205.21K |
Cash from Financing | 4M | 1.87M | 3.33M | 2.65M | 13.42M | -44.6K | 1.59M | 10.32M | 6.05M | 5.17M |
Debt Issued (Net) | -50K | 0 | 0 | -13.83K | -66.69K | -44.6K | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 1000K | 1000K | 2.01M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 1M | 0 | 4.02M | 0 | 0 | 6.11M | 0 | 0 |
Net Change in Cash | 2.44M▲ 0% | -806.15K▼ 133.0% | -442.04K▲ 45.2% | 8.6K▲ 101.9% | 9.62M▲ 111781.5% | -5.1M▼ 153.0% | -4.46M▲ 12.6% | 5.15M▲ 215.4% | -4.7M▼ 191.3% | -3.8M▲ 0% |
Free Cash Flow | -1.56M▲ 0% | -2.6M▼ 67.4% | -3.77M▼ 45.0% | -2.65M▲ 29.7% | -4.07M▼ 53.4% | -4.93M▼ 21.1% | -6.05M▼ 22.8% | -5M▲ 17.3% | -10.48M▼ 109.4% | -8.71M▲ 0% |
FCF Margin % | -2444.43% | -600.84% | -1695.67% | -842.6% | -563.02% | -1929.76% | -2674.9% | -1077.38% | -1483.88% | -1668.28% |
FCF Growth % | -128.44% | -67.35% | -44.99% | 29.73% | -53.41% | -21.12% | -22.77% | 17.33% | -109.42% | -30.18% |
FCF per Share | -0.79 | -1.10 | -1.46 | -0.96 | -0.93 | -0.84 | -0.91 | -0.40 | -0.58 | -0.41 |
FCF Conversion (FCF/Net Income) | 0.83x | 0.38x | 0.73x | 0.67x | 0.99x | 0.67x | 0.88x | 0.86x | 0.88x | 0.81x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 13.92K | 12.98K | 16.3K | 4.78K | 8.21K | 10.04K | 0 | 0 |
LEXX Key Ratios
Lexaria Bioscience Corp. (LEXX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -130.92% | -255.97% | -168.05% | -158.22% | -51.81% | -70.25% | -129.26% | -112.11% | -231.96% | -238.6% |
Return on Invested Capital (ROIC) | -911.5% | -1048.56% | -331.46% | -242.86% | -230.81% | -237.12% | -291.59% | -306.37% | -790.85% | -1340.52% |
Gross Margin | 50.91% | 93.66% | -87.16% | 22.02% | 75.74% | 18.29% | 23.86% | 82.56% | 83.2% | 84.9% |
Net Margin | -2937.31% | -1522.97% | -1841.53% | -1249.71% | -557.19% | -2846.3% | -2946.36% | -1248.25% | -1686% | -2067.65% |
Debt / Equity | 0.02x | 0.00x | - | 0.06x | 0.01x | 0.01x | 0.06x | 0.02x | 0.04x | 0.02x |
Interest Coverage | -319.78x | - | - | - | - | - | - | - | - | - |
FCF Conversion | 0.83x | 0.38x | 0.73x | 0.67x | 0.99x | 0.67x | 0.88x | 0.86x | 0.88x | 0.81x |
Revenue Growth | 56.29% | 580.85% | -48.62% | 41.41% | 129.59% | -64.66% | -11.43% | 105.24% | 52.05% | 5.05% |
Related:LEXX Dividend History·LEXX Revenue History·LEXX Price History·LEXX P/E History·LEXX Financial Ratios·LEXX Institutional Holders
LEXX Frequently Asked Questions
Lexaria Bioscience Corp. (LEXX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lexaria Bioscience Corp. (LEXX) reported $0.5M in revenue for fiscal year 2025. This represents a 2471% increase from $0.0M in 2006.
Lexaria Bioscience Corp. (LEXX) grew revenue by 52.0% over the past year. This is strong growth.
Lexaria Bioscience Corp. (LEXX) reported a net loss of $10.8M for fiscal year 2025.
Dividend & Returns
Lexaria Bioscience Corp. (LEXX) has a return on equity (ROE) of -232.0%. Negative ROE indicates the company is unprofitable.
Lexaria Bioscience Corp. (LEXX) had negative free cash flow of $8.7M in fiscal year 2025, likely due to heavy capital investments.